Russell Investments Group, Ltd. Iveric Bio, Inc. Transaction History

Russell Investments Group, Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$26.24 - $39.63 $156,075 - $235,719	-5,948 Reduced 6.65%	83,461 $3.28 Million
Q1 2023 May 09, 2023	BUY	$18.67 - $24.56 $160,730 - $211,437	8,609 Added 10.65%	89,409 $2.18 Million
Q1 2022 May 05, 2022	SELL	$12.15 - $16.83 $29,670 - $41,098	-2,442 Reduced 2.93%	80,800 $1.36 Million
Q4 2021 Jan 21, 2022	SELL	$13.83 - $18.78 $13,719 - $18,629	-992 Reduced 1.18%	83,242 $1.39 Million
Q3 2021 Nov 08, 2021	BUY	$7.07 - $17.5 $24,278 - $60,095	3,434 Added 4.25%	84,234 $1.37 Million
Q1 2021 May 10, 2021	BUY	$5.08 - $6.89 $410,464 - $556,712	80,800 New	80,800 $499,000
Q3 2020 Nov 09, 2020	SELL	$4.01 - $6.29 $35,833 - $56,207	-8,936 Closed	0 $0
Q2 2020 Aug 05, 2020	BUY	$3.06 - $6.6 $4,840 - $10,441	1,582 Added 21.51%	8,936 $47,000
Q1 2020 May 06, 2020	BUY	$2.83 - $8.44 $20,811 - $62,067	7,354 New	7,354 $25,000
Q3 2019 Nov 01, 2019	SELL	$1.09 - $1.29 $30,683 - $36,313	-28,150 Closed	0 $0
Q2 2019 Aug 09, 2019	BUY	$1.21 - $1.48 $34,061 - $41,662	28,150 New	28,150 $37,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.